Colorescience announces the results of a study suggesting clinical advancements to reduce redness associated with rosacea.

The 18-week study, published inĀ The Journal of Cosmetic Dermatology, assessed the efficacy and tolerability of a daily use, multifunctional topical skin care regimen (All Calm Clinical Redness Corrector SPF 50 andĀ Sunforgettable Brush-On Shield SPF 50) alone and in combination with Intense Pulsed Light Therapy (IPL) to improve facial redness associated with skin conditions such as rosacea and decrease post treatment side effects.

“The study showed that this regimen can achieve significant improvement for patients who suffer with facial redness. Having products like these that work alone or in combination with office-based procedures is a game changer for aesthetic practices,” says clinical study investigator Jennifer Deaver Peterson, MD, from The Pearl Dermatology in Houston, in a media release from Colorescience.

In the study, 20 patients used a daily topical skin care regimen for 12 weeks. At week 12, those same patients received a single IPL (M22 Lumenis) treatment immediately followed by the application of the same skin care products and then continued the topical skin care regimen for 6 additional weeks.

All patients (100%) reported their skin looked better immediately following the application of the skin care products across all time points, including immediately post IPL. At week 18, the overall mean redness score significantly improved by 33% from baseline (p<0.01).

This study demonstrates that the skincare regimen applied immediately post IPL and in combination with an IPL treatment produced a significant reduction in overall facial redness in patients with rosacea, the release explains.

“Our mission is to develop unique products that improve patient experiences, enhance outcomes and protect skin health,” says Patricia Boland, vice president, research and development, Colorescience, in the release. “We are pleased that these results are consistent with our other published data and what our physician partners see in practice.”

[Source(s): Colorescience, PR Newswire]